2018 American Transplant Congress
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…2018 American Transplant Congress
Immunoglobulin Replacement Therapy in Pediatric Renal Transplant Patients
University of Iowa Hospitals and Clinics, Iowa City, IA.
Immunoglobulin replacement therapy decreases infection frequency in patients with primary immunodeficiency; however, there is limited data regarding the use of intravenous immunoglobulin (IVIG) or subcutaneous…2017 American Transplant Congress
Effect of Everolimus-Based Immunosuppressive Regimen on New Onset of Diabetes After Kidney Transplantation – A 24 Month Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Oslo, Norway; 2Novartis Pharma AG, Basel, Switzerland
Purpose: New onset diabetes after transplantation (NODAT) is a common metabolic complication which affects long-term patient survival and graft outcomes. Most of the immunosuppressive drugs…2017 American Transplant Congress
First Report of Human Liver Transplantation After Normothermic Machine Perfusion (NMP) in the United States.
NMP is a novel preservation method for liver grafts. We transplanted 10 human livers after NMP to test the safety and feasibility of NMP on…2017 American Transplant Congress
We Wish This Would Never Happen Again! Implementation of an Adverse Event Review System to Improve the Safety of Pediatric Solid Organ Transplant (SOT) Patients.
Background: 50% of SOT centers are cited by CMS for inadequate review of adverse events (AE)s. AE reviews are inconsistently performed, rarely cover near misses…2017 American Transplant Congress
IVIg+Rituximab Desensitization (DES) Combined with Alemtuzumab (ATZ) Induction Does Not Increase Risk for Viral Infections (VIs) and Associated Complications in HLA-Sensitized (HS) Kidney Transplant Patients (KTx Pts).
Background: VIs represent significant morbidity factors in KTx pts. DES followed by KTx with ATZ induction increased successful Tx rates in HS pts, but may…2017 American Transplant Congress
Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients.
Pharmacy, Northwestern Memorial Hospital, Chicago, IL
Background:The elderly population (≥ 65 years) comprise one fourth of patients on the waiting list for renal transplantation. Alemtuzumab use has increased over the past…2017 American Transplant Congress
Donor Derived Transmission Events in 2015-2016: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
1DTAC, Richmond; 2United Network for Organ Sharing, Richmond
The OPTN DTAC, a multidisciplinary committee, evaluates potential donor derived transmission events (PDDTE), including mostly infections (I) & malignancies (M), to assess for likelihood of…2017 American Transplant Congress
A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.
This phase 2, double-blind, randomised controlled study (BEL114424) explores the safety and potential efficacy of addition of belimumab to standard of care in renal transplantation…2017 American Transplant Congress
Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.
Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 19
- Next Page »